SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 206.36+1.4%Nov 26 3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: dwc who wrote (22300)6/16/1998 11:13:00 AM
From: Henry Niman  Read Replies (1) of 32384
 
LGND presents at many conferences and some slip through the cracks (they just presented at ASCO and the ADA meeting and will soon be at the International AIDS meeting in Stockholm.

The experiment isn't that unexpected, but the result was quite striking. Here's the abstract of the earlier paper which led to the current results (to be published in another paper):

Cancer Res 1998 Feb 1;58(3):479-484

Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069
(TARGRETIN) causes complete regression of mammary carcinoma.

Bischoff ED, Gottardis MM, Moon TE, Heyman RA, Lamph WW

Department of Retinoid Research, Ligand Pharmaceuticals, Inc., San Diego, California 92121, USA.

Recently, we reported that LGD1069, a high-affinity ligand for the retinoid X receptors (RXRs), was shown to have an efficacy
equivalent to that of tamoxifen (TAM) as a chemopreventive agent in the N-nitroso-N-methylurea-induced rat mammary
carcinoma model. Furthermore, LGD1069 was very well tolerated during 13 weeks of chronic therapy with no classic signs of
"retinoid-associated" toxicities. Due to the high efficacy and benign profile of this RXR agonist as a suppressor of carcinogenesis,
we examined its role as a therapeutic agent on established mammary carcinomas. In the rat mammary carcinoma model,
N-nitroso-N-methylurea was used to induce tumors, and the tumors were allowed to grow to an established size prior to initiation
of treatment. LGD1069-treated animals showed complete regression in 72% of treated tumors and had a reduced tumor load
compared to control. In addition, the combination of LGD1069 and TAM showed increased efficacy over either agent alone.
Histopathological analysis showed a reduction of LGD1069-treated tumor malignancy, an increase in differentiation, and a sharp
decrease in cellular proliferation compared to vehicle-treated control tumors. These data demonstrate that the RXR-selective
ligand LGD1069 is a highly efficacious therapeutic agent for mammary carcinoma and enhances the activity of TAM.

PMID: 9458093, UI: 98117297
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext